Top Markets
Coin of the day
American CryoStem Corporation American CryoStem Corporation

American CryoStem Corporation

CRYO
Pozycja w akcjach #42083
American CryoStem Corporation (ACSC) specializes in the development,... American CryoStem Corporation (ACSC) specializes in the development, commercialization, and licensing of technologies derived from adipose (fat) tissue, primarily for applications within regenerative and personalized medicine. Among its key offerings is the CELLECT system, designed to streamline tissue sample collection, transportation, and storage for medical practitioners. The company also provides the ATGRAFT service, a comprehensive solution for harvesting, processing, and preserving adipose tissue, enabling physicians to offer patients versatile options for tissue products and cellular banking. Complementing these are ATCELL, a line of proprietary adipose-derived stem cells, and ACSelerat cell culture media, specifically formulated to promote the growth of human stromal cells. Furthermore, American CryoStem extends its expertise through contract manufacturing services for specific formulations, including Autokine-CM, an anti-aging topical product, and a unique autologous skin care range. Founded in 1987, American CryoStem Corporation is headquartered in Eatontown, New Jersey.
Cena akcji
$0.0001
Ostatnia synchronizacja: 2024-04-02
Kapitalizacja rynkowa
$5.03K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel American CryoStem Corporation (CRYO)

Kategoria

Zyski dla American CryoStem Corporation (CRYO)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych American CryoStem Corporation, obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy American CryoStem Corporation od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$5.27B -
US
$1.95B -
NL
- -
CH
$3.01B -
BE
- -
KR